ストックスクリーナーアプリを入手
24.71
1.89%
-0.475
アフターアワーズ：
24.65
-0.065
-0.26%
前日終値:
$25.19
開ける：
$25.28
24時間の取引高:
6.68M
Relative Volume:
0.61
時価総額：
$10.36B
収益：
$5.06B
当期純損益:
$-2.22B
株価収益率:
-4.2466
EPS:
-5.82
ネットキャッシュフロー:
$-3.96B
1週間 パフォーマンス:
+0.88%
1か月 パフォーマンス:
-28.80%
6か月 パフォーマンス:
-54.92%
1年 パフォーマンス:
-76.11%
1日の値動き範囲:
$24.43
$25.28
1週間の範囲:
$24.26
$27.21
52週間の値動き範囲:
$23.15
$170.47
Moderna Inc Stock (MRNA) Company Profile
MRNA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
24.71 | 10.36B | 5.06B | -2.22B | -3.96B | -5.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-13 | 開始されました | Citigroup | Neutral |
| 2025-02-18 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-01-29 | ダウングレード | Goldman | Buy → Neutral |
| 2024-12-18 | ダウングレード | Argus | Buy → Hold |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-19 | 開始されました | Berenberg | Hold |
| 2024-11-18 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-09-13 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2024-09-13 | ダウングレード | Jefferies | Buy → Hold |
| 2024-09-13 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-08-28 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-08-07 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-08-05 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2024-01-02 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 開始されました | Canaccord Genuity | Hold |
| 2023-11-03 | アップグレード | HSBC Securities | Reduce → Hold |
| 2023-11-02 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2023-08-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 開始されました | William Blair | Mkt Perform |
| 2023-07-14 | 開始されました | HSBC Securities | Reduce |
| 2023-06-26 | アップグレード | UBS | Neutral → Buy |
| 2023-04-26 | 開始されました | Guggenheim | Neutral |
| 2023-03-13 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-02-24 | ダウングレード | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | アップグレード | Jefferies | Hold → Buy |
| 2022-12-14 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | アップグレード | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | アップグレード | Deutsche Bank | Hold → Buy |
| 2022-02-01 | アップグレード | Redburn | Sell → Neutral |
| 2022-01-26 | アップグレード | Deutsche Bank | Sell → Hold |
| 2022-01-21 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 開始されました | UBS | Neutral |
| 2021-12-07 | 開始されました | Cowen | Market Perform |
| 2021-11-09 | 開始されました | Wolfe Research | Outperform |
| 2021-10-22 | 開始されました | Deutsche Bank | Sell |
| 2021-10-15 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-08-06 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 繰り返されました | Jefferies | Hold |
| 2021-02-01 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-12-16 | ダウングレード | Jefferies | Buy → Hold |
| 2020-12-16 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | ダウングレード | Needham | Buy → Hold |
| 2020-11-23 | 開始されました | Wells Fargo | Equal Weight |
| 2020-11-17 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-07-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 開始されました | Jefferies | Buy |
| 2020-06-30 | 開始されました | Argus | Buy |
| 2020-06-08 | 開始されました | Barclays | Overweight |
| 2020-04-30 | 開始されました | BMO Capital Markets | Outperform |
| 2020-03-05 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 再開されました | BofA/Merrill | Buy |
| 2019-10-25 | 開始されました | ROTH Capital | Buy |
| 2019-04-05 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Moderna Inc (MRNA) 最新ニュース
Moderna (MRNA) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years - Benzinga
Invesco Ltd. Acquires 979,858 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Says New Drug Plant Riddled With Defects, Mold - Law360
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Legal & General Group Plc - MarketBeat
Moderna (MRNA) Leads Healthcare Short Interest in March - GuruFocus
Lansdowne Partners UK LLP Acquires New Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Shares Acquired by Advisory Services Network LLC - MarketBeat
Quinn Opportunity Partners LLC Invests $686,000 in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Neuberger Berman Group LLC Reduces Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Bloom Energy, Rogers, 3D Systems, Moderna, and EchoStar Stocks Trade Down, What You Need To Know - The Globe and Mail
Moderna permitted to start commercial mRNA vaccine manufacture in UK - The Pharma Letter
Leerink Partners Adjusts Moderna Price Target to $23 From $27, Maintains Underperform Rating - MarketScreener
Moderna Co-Founder and MIT Legend Strengthens Decoy Therapeutics Drug Development Team - Stock Titan
MRNA Based Vaccines and Therapeutics Therapeutics Market Size - openPR.com
Moderna, Inc. (NASDAQ:MRNA) Stake Decreased by Bank of Montreal Can - MarketBeat
Renaissance Technologies LLC Purchases 700,458 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
APG Asset Management N.V. Buys 203,792 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
FDA Special Assistant Høeg’s Vaccine Concerns On Display At ACIP - insights.citeline.com
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Shelton Capital Management - MarketBeat
Goldman Sachs Adjusts Moderna's Price Target to $35 From $49, Keeps Neutral Rating - MarketScreener
Russell Investments Group Ltd. Purchases 76,350 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Redburn Atlantic Adjusts Moderna's Price Target to $52 From $55, Keeps Neutral Rating - MarketScreener
Morgan Stanley Issues Pessimistic Forecast for Moderna (NASDAQ:MRNA) Stock Price - MarketBeat
Aviva PLC Lowers Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Resona Asset Management Co. Ltd. Buys Shares of 94,753 Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Fmr LLC Has $776.08 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Sit Investment Associates Inc. Sells 10,675 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna (NASDAQ:MRNA) Sets New 1-Year LowTime to Sell? - MarketBeat
Lobbying Update: $50,000 of MODERNA US INC. lobbying was just disclosed - Nasdaq
Aster Capital Management DIFC Ltd Takes Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
RFK Jr Asks If Taxpayer-Funded Healthcare Should Be Accessible To People Smoking 'Three Packs A Day' - Benzinga
First Week of May 30th Options Trading For Moderna (MRNA) - Nasdaq
Himension Capital Singapore PTE. LTD. Has $1.31 Million Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
National Bank of Canada FI Decreases Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
87,970 Shares in Moderna, Inc. (NASDAQ:MRNA) Acquired by ExodusPoint Capital Management LP - MarketBeat
Titleist Asset Management LLC Has $1.31 Million Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna to Report First Quarter 2025 Financial Results on Thursd - GuruFocus
Schroder Investment Management Group Sells 103,486 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Novavax (NVAX) Shares Plunge After RFK Jr. Questions Its Covid Vaccine Efficacy - Bloomberg.com
MRNA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Moderna, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Is Moderna Stock A Sell After The FDA's 'Bloodbath?' - Investor's Business Daily
Japan approves Moderna COVID vaccine as booster, Novavax files for 1st approval - tuoitrenews.vn
Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 - Eagle-Tribune
Press Release Distribution & PR Platform - ACCESS Newswire
Moderna Q1 Earnings Date Revealed: Key Details for Investors - Stock Titan
MRNA Stock To Rise 2x? - Forbes
Geode Capital Management LLC Purchases 171,774 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Inc (MRNA) 財務データ
収益
当期純利益
現金流量
EPS
2.51%
大文字化:
|
ボリューム (24 時間):